AMPK signaling pathways are potential targets for the treatment of metabolic disorders, including obesity, insulin resistance, and nonalcoholic fatty liver disease (NAFLD) [23,24]. Here, PRKAA1 is linked to metabolic dysfunction-associated steatotic liver disease.